A massive genetic study found that naturally lower cholesterol is linked to a dramatically reduced risk of dementia. The ...

Two widely available medicines can safely improve brain health in those with early Alzheimer’s disease, a new study has found ...

The team found a notable correlation between genetics that predicted low cholesterol and a lower risk of dementia, suggesting ...

These biotech IPOs plan to move forward during shutdown © 2025 American City Business Journals. All rights reserved. Use of ...

Health Canada has authorized a drug shown to slow the progression of Alzheimer's disease. Lecanemab is the first medication ...

Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...

Controversial anti-amyloid therapies costing up to $32,000 annually offer modest hope for Alzheimer's patients while carrying ...

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...

Village Caregiving reports that in-home care for seniors with dementia fosters independence, safety, and companionship, ...

The NDA submission is supported by data from two pivotal Phase 3 clinical trials, which evaluated MK-6240’s performance in detecting tau pathology in early Alzheimer’s disease. These studies met their ...

However, lecanemab doesn’t stop the relentless march of Alzheimer’s disease, it just slows it down. The medication, sold under the brand name Leqembi, also comes with a hefty price tag and a risk of ...

Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.